Literature DB >> 29128026

Hepatopulmonary Syndrome and Portopulmonary Hypertension: Implications for Liver Transplantation.

Shaz Iqbal1, Kerri Akaya Smith2, Vandana Khungar3.   

Abstract

Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH) represent serious pulmonary complications of advanced liver diseases. Orthotopic liver transplantation (OLT) is capable of completely resolving the underlying abnormalities associated with HPS. On the other hand, post-OLT response in patients with PoPH is less predictable, although heavily influenced by pre-OLT mean pulmonary arterial pressure. It remains the case that the opportunity to reverse 2 potentially fatal organ dysfunctions in the liver and the lung make HPS and PoPH more than worthy for further clinical investigations.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Hepatopulmonary; Portopulmonary; Transplant

Mesh:

Year:  2017        PMID: 29128026     DOI: 10.1016/j.ccm.2017.08.002

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  10 in total

Review 1.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

2.  Implications of BMP9/10 for patients with liver cirrhosis.

Authors:  Dong Ji; Guofeng Chen; Yongping Yang
Journal:  EBioMedicine       Date:  2020-07-03       Impact factor: 8.143

Review 3.  Liver transplantation in the era of COVID-19.

Authors:  Mohamed El Kassas; Mohamed Alboraie; Amira Al Balakosy; Nermeen Abdeen; Shimaa Afify; Mohammad Abdalgaber; Ahmed F Sherief; Ahmad Madkour; Mohamed Abdellah Ahmed; Mohamed Eltabbakh; Mohamed Salaheldin; Mohamed-Naguib Wifi
Journal:  Arab J Gastroenterol       Date:  2020-05-12       Impact factor: 2.076

4.  Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.

Authors:  Erika B Rosenzweig; Steven H Abman; Ian Adatia; Maurice Beghetti; Damien Bonnet; Sheila Haworth; D Dunbar Ivy; Rolf M F Berger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

5.  Krüppel-like factor 6 mediates pulmonary angiogenesis in rat experimental hepatopulmonary syndrome and is aggravated by bone morphogenetic protein 9.

Authors:  Yihui Yang; Hongfu Yu; Congwen Yang; Yunfei Zhang; Xiangfa Ai; Xiaobo Wang; Kaizhi Lu; Bin Yi
Journal:  Biol Open       Date:  2019-06-26       Impact factor: 2.422

6.  Hepatocyte-derived exosomal MiR-194 activates PMVECs and promotes angiogenesis in hepatopulmonary syndrome.

Authors:  Lin Chen; Yi Han; Yujie Li; Bing Chen; Xuehong Bai; Karine Belguise; Xiaobo Wang; Yang Chen; Bin Yi; Kaizhi Lu
Journal:  Cell Death Dis       Date:  2019-11-07       Impact factor: 8.469

Review 7.  Chinese guidelines on the management of liver cirrhosis (abbreviated version).

Authors:  Xiao-Yuan Xu; Hui-Guo Ding; Wen-Gang Li; Jing-Hang Xu; Ying Han; Ji-Dong Jia; Lai Wei; Zhong-Ping Duan; En-Qiang Ling-Hu; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2020-12-07       Impact factor: 5.742

8.  Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum.

Authors:  Zakiyah Kadry; Eric Schaefer; Karen Krok; Alison Faust; Jonathan Gibson Stine; Ian Roy Schreibman; Dmitri Bezinover; Thomas Roberts Riley
Journal:  JHEP Rep       Date:  2021-08-12

9.  Case report: Rare abernethy malformation with hepatopulmonary syndrome in a pediatric patient.

Authors:  Lianfu Ji; Zhaoming Ji; Dandan Xiang; Yuming Qin; Shiwei Yang
Journal:  Front Pediatr       Date:  2022-09-09       Impact factor: 3.569

10.  To: The Perme scale score as a predictor of functional status and complications after discharge from the intensive care unit in patients undergoing liver transplantation.

Authors:  Márcio Ferreira Camillis; Lucas Galant; Leonardo Miguel Correa Garcia; Ricardo Wickert; Priscila Cidade; Cassiano Teixeira
Journal:  Rev Bras Ter Intensiva       Date:  2019 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.